# Systematic Review Protocol for Animal Intervention Studies

**Format by SYRCLE ([www.syrcle.nl](http://www.syrcle.nl))**  
**Version 1.0 (July 2014)**

<table>
<thead>
<tr>
<th>Item #</th>
<th>Section/item</th>
<th>Description</th>
<th>Check for approval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Title of the review</td>
<td>A Systematic Review of the Modifying Effect of Anaesthetic Drugs on Metastasis in Animal Models for Cancer</td>
<td></td>
</tr>
</tbody>
</table>
| 2. | Authors (names, affiliations, contributions) | Carlijn R Hooijmans; designing and performing research, analysing data, writing paper  
Merel Ritskes-Hoitinga; designing research, writing paper  
Gert-Jan Scheffer; designing research, writing paper  
Florentine J Geessink; performing research: data extraction, Quality assessment | |
| | | Departments of SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE), Anesthesiology, Medical Library, Radboud UMC Nijmegen, The Netherlands. | |
| 3. | Other contributors (names, affiliations, contributions) | Alice Tillema; search strategy design Moira Bruintjes; performing research; In- and exclusion  
Marleen Egberink; performing research; In and exclusion and data extraction  
Sandra de Groot; performing research; data extraction and quality assessment  
Marieke Schouten; performing research; data extraction and quality assessment | |
| | | | |
| 4. | Contact person + e-mail address | Carlijn R Hooijmans; Carlijn.Hooijmans@radboudumc.nl | |
| 5. | Date of protocol registration | | |
| **Background** | | | |
| 6. | What is already known about this disease/ model/ intervention? Why is it important to do this review? | Despite the progress made in cancer treatment, distant metastasis or local recurrence after primary tumour resection remain a major clinical problem. As a consequence, a lot of research concentrates on exploring factors that might influence the metastatic process. One of the factors that has been suggested to influence tumour reoccurrence or metastasis is the anaesthetic technique applied during or immediately after oncologic surgery. Many published clinical studies are retrospective and suffer from confounding, most studies investigate combinations of anaesthetic and analgesic drugs, which makes it a challenge to isolate the contribution of a specific drug. Large-scale RCTs are needed to prove a causal link between anaesthetic techniques and metastasis. Some multicentre trials have been launched, but while we await their results, we could further evaluate this link in animal studies. We will conduct the first SR and MA of the effect of anaesthetic drugs on metastasis in experimental cancer models. We will provide: 1) a complete and systematic overview of all animal studies on this topic; 2) insight into | |
### Objectives of this SR

7. Specify the disease / health problem of interest
   - Metastasis/ metastatic spread in experimental cancer

8. Specify the population /species studied
   - All species

9. Specify the intervention/exposure
   - Anesthetic drugs (used in the clinical setting)

10. Specify the control population
    - No anesthetic drugs (placebo or sham or no intervention)

11. Specify the outcome measures
    - 1) Number of metastasis
        - 2) Metastasis incidence

12. State your research question (based on points 7-11)
    - Does analgesic treatment reduce the number or incidence of metastasis in experimental cancer

### Methods:

#### Search and study identification

13. Identify literature databases to search (e.g. Pubmed, Embase, Web of science)
    - XMEDLINE via PubMed
    - XWeb of Science
    - XSCOPUS
    - XEMBASE

14. Define electronic search strategies (e.g. use the [step by step search guide](#) and animal search filters [2, 3])
    - When available, please add a supplementary file containing your search strategy: see [supplementary file](#)

15. Identify other sources for study identification
    - XReference lists of included studies
    - XReference lists of relevant reviews
    - XConference proceedings, namely:
    - XContacting authors/ organisations, namely:
    - XOther, namely:

16. Define search strategy for these other sources
    - Screening the reference lists for relevant titles and screening the abstracts of these relevant titles

#### Study selection phases

17. Define screening phases (e.g. pre-screening based on title/abstract, full text screening, both)
    - 1) screening based on title and abstract
    - 2) full-text screening of the eligible articles

18. Specify number of reviewers per screening phase
    - Each phase: 2 independent observers per article. Phase 1: CH and MB screen all papers. Phase 2: CH and ME screen all papers. Differences will be solved through discussion or by consulting a fourth investigator

#### Study selection criteria. Define all inclusion and exclusion criteria based on:

19. Type of study (design)
    - Inclusion criteria: Comparison of anaesthetic drug used in clinical practice versus no anaesthetic drug on number of metastasis or metastasis incidence in animals with experimental cancer
    - Exclusion criteria: Co-interventions/ contamination

20. Type of animals/ population (e.g. age, gender, disease model)
    - Inclusion criteria: animals with experimental cancer in which metastasis can develop
    - Exclusion criteria: Co-morbidities, ex vivo, in vitro, in silico, experimental cancer without metastasis.
| 21. | Type of intervention (e.g. dosage, timing, frequency) | Inclusion criteria: anaesthetic drug used  
Exclusion criteria: anesthetic drugs not used in the clinical setting |
| 22. | Outcome measures | Inclusion criteria: number of metastasis or metastasis incidence  
Exclusion criteria: weight of metastasis, surface covered with metastasis, number of occupied bones, number of invading cells |
| 23. | Language restrictions | Inclusion criteria: all languages  
Exclusion criteria: none |
| 24. | Publication date restrictions | Inclusion criteria: all publication dates  
Exclusion criteria: none |
| 25. | Other | Inclusion criteria:  
Exclusion criteria: Reviews or non original papers |
| 26. | Sort and prioritize your exclusion criteria per selection phase | Selection phase 1:  
1. Review  
2. Human study  
3. Not in vivo  
4. No metastases/ only primary tumor  
5. No control group  
6. Combination therapy or contamination  
7. Not about anaesthetics used in the clinic  
Selection phase 2:  
1. Review  
2. Human study  
3. Not in vivo  
4. No metastases/ only primary tumor  
5. No control group  
6. Combination therapy or contamination  
7. Not about analgesics used in the clinic  
8. No relevant outcome measure |
| 27. | Study ID (e.g. authors, year) | Authors, title, year, language, contact author e-mail |
| 28. | Study design characteristics (e.g. experimental groups, number of animals) | Number of animals in experimental and control groups, presence of control group |
| 29. | Animal model characteristics (e.g. species, gender, disease induction) | Animal species, strain, age or weight, gender, cancer model (transgenic or induced), type of cells/ drugs used to induce cancer, type of cancer, amount of cells, location of injection of tumor cells, type of anesthetics used to create model |
| 30. | Intervention characteristics (e.g. intervention, timing, duration) | Type of drugs, Route of administration, dose, frequency, timing relative to tumor cell injection, duration of treatment, type of control group |
| 31. | Outcome measures | Number of metastasis, incidence of metastasis |
| 32. | Other (e.g. drop-outs) | Age of sacrificing animals, anesthetics used for sacrificing, region of metastasis count |
| 33. | Risk of bias assessment (internal validity) |  |
| 34. | Specify the number of reviewers assessing the risk of bias in each study | 2 |
| 34. | Define criteria to assess the internal validity of included studies (e.g. selection, performance, detection and attrition bias) | ☑ By use of SYRCLE’s Risk of Bias tool [4]  
☒ By use of SYRCLE’s Risk of Bias tool, adapted as follows: addition of 2 reporting items; 1) reporting of randomisation at any level 2) reporting of blinding at any level.  
☐ By use of CAMARADES’ study quality checklist, e.g. [5]  
☐ By use of CAMARADES’ study quality checklist, adapted as follows:  
☐ Other, namely: |
| 35. | For each outcome measure, define the type of data to be extracted (e.g. continuous/ dichotomous, unit of measurement) | Number of metastasis: continuous  
Incidence of metastasis: Continuous (% or number of animals in control and experimental group with metastasis) |
| 36. | Methods for data extraction/retrieval (e.g. first extraction from graphs using a digital screen ruler, then contacting authors) | First extraction from graphs using universal desktop ruler software (http://avpsoft.com/products/udruler/) by two independent reviewers. If data could not be extracted from text or figures authors will be contacted via e-mail (max. 3 e-mails). |
| Collection of outcome data | | |
| 37. | How you are planning to combine/compare the data (e.g. descriptive summary, meta-analysis) | Meta-analysis with subgroup analysis and sensitivity analysis for all outcome measures |
| 38. | How the decision as to whether a meta-analysis will be performed will be made | A minimum of 2 articles per outcome measure is required  
No restrictions in terms of heterogeneity will be applied, instead, sources of heterogeneity will be investigated through sensitivity and subgroup analysis. |
| Data analysis/synthesis. Specify (per outcome measure): | | |
| 39. | The effect measure to be used (e.g. mean difference, standardized mean difference, risk ratio, odds ratio) | Number of metastases: SMD  
Incidence of metastasis: RR |
| 40. | The statistical model of analysis (e.g. random or fixed effects model) | Random effects model |
| 41. | The statistical methods to assess heterogeneity (e.g. \( \Gamma^2 \), Q) | \( \Gamma^2 \) |
| 42. | Which study characteristics will be examined as potential source of heterogeneity (subgroup analysis) | Anesthetic technique  
Type of drug (volatile, barbiturates, ketamin, propofol)  
Species  
Gender  
Region of metastasis  
Timing and duration of treatment  
* Subgroup analyses are only performed when a minimum of 3 studies or 5 independent comparisons are available |
| 43. | The method for assessment of publication bias | Funnel plots, performing Duval and Tweedie's trim and fill analysis |
| 44. | Any sensitivity analyses you propose to perform | Impact of single or multiple use of anaesthetic drug treatment: |
| impact of excluding other species than rodents; impact of recalculating median and ranges into means and SDs |
|---|---|

**Final approval by (names, affiliations):** Carlijn Hooijmans  
**Date:** 01-09-2014